Search

Displaying results 1021 - 1030 of 8696 in total
  1. Drug

    Tyrosine

    go.drugbank.com/drugs/DB00135
    ApprovedInvestigationalNutraceutical

    Tyrosine is a non-essential amino acid. In animals it is synthesized from phenylalanine. It is also the precursor of epinephrine, thyroid hormones, and melanin.

    Synonyms: (S)-3-(p-Hydroxyphenyl)alanine, (−)-α-amino-p-hydroxyhydrocinnamic acidMixtures: Aminosyn-PF, Aminosyn-PF
  2. Target

    MAP kinase-activated protein kinase 3

    go.drugbank.com/bio_entities/BE0004064
    TargetHumans

    Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. … Involved in toll-like receptor signaling pathway (TLR) in dendritic cells: required for acute TLR-induced macropinocytosis by phosphorylating and activating RPS6KA3.

    Polypeptides: MAP kinase-activated protein kinase 3
  3. Target

    MAP/microtubule affinity-regulating kinase 3

    go.drugbank.com/bio_entities/BE0009481
    TargetHumans

    Serine/threonine-protein kinase (PubMed:16822840, PubMed:16980613, PubMed:23666762). Involved in the specific phosphorylation of microtubule-associated proteins for MAP2 and MAP4. Phosphorylates the microtubule-associated protein MAPT/TA...

    Polypeptides: MAP/microtubule affinity-regulating kinase 3
  4. Target

    MAP kinase-activated protein kinase 2

    go.drugbank.com/bio_entities/BE0001373
    TargetHumans

    Following stress, it is phosphorylated and activated by MAP kinase p38-alpha/MAPK14, leading to phosphorylation of substrates. … Involved in toll-like receptor signaling pathway (TLR) in dendritic cells: required for acute TLR-induced macropinocytosis by phosphorylating and activating RPS6KA3

    Polypeptides: MAP kinase-activated protein kinase 2
  5. Target

    MAP/microtubule affinity-regulating kinase 4

    go.drugbank.com/bio_entities/BE0009482
    TargetHumans

    Serine/threonine-protein kinase (PubMed:14594945, PubMed:15009667, PubMed:23184942, PubMed:23666762). Phosphorylates the microtubule-associated protein MAPT/TAU (PubMed:14594945, PubMed:23666762). Also phosphorylates the microtubule-asso...

    Polypeptides: MAP/microtubule affinity-regulating kinase 4Synonyms: MAP/microtubule affinity-regulating kinase-like 1
  6. Drug

    Clostridium botulinum

    go.drugbank.com/drugs/DB14223
    Investigational

    Products: DYSPORT FOR INJECTION 300u/vial, DYSPORT FOR INJECTION 500 u/vial
  7. Drug

    Sodium hydroxide

    go.drugbank.com/drugs/DB11151
    Approved

    Interestingly, sodium hydroxide has been studied for its use in the treatment of prion disease (as occurs in mad cow disease and kuru). … When dissolved in water or neutralized with acid it releases substantial amounts of heat, which may prove sufficient to ignite combustible materials. Sodium hydroxide is highly corrosive [L1965].

    Mixtures: OMEGA PLUS EMULSION FOR INFUSION, OMEGA SPECIAL EMULSION FOR INFUSION
  8. Drug

    Fazpilodemab

    go.drugbank.com/drugs/DB18924
    Investigational

    Fazpilodemab is under investigation in clinical trial NCT04171765 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-alcoholic Steatohepatitis).

    Synonyms: Anti-fgfr1/klb mab, immunoglobulin G1-kappa, anti-[Homo sapiens KLB (klotho beta, b-Klotho)] and anti-[Homo sapiens FGFR1 (fibroblast growth factor receptor 1, FLT2, KAL2)], monoclonal antibody, bispecific; gamma1 heavy chain
  9. Drug

    Magnesium hydroxide

    go.drugbank.com/drugs/DB09104
    ApprovedInvestigational

    It can also be used topically as a deodorant or for the relief of canker sores (aphthous ulcers). … Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form.

    Mixtures: Mag-Al, Mag-AL PlusCategories: Drugs for Acid Related Disorders
  10. Drug

    Cosibelimab

    go.drugbank.com/drugs/DB15770
    ApprovedInvestigational

    On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the … Cosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1).

    Categories: Programmed Death Receptor-1 Blocking AntibodySynonyms: anti-Pd-l1 monoclonal antibody CK-301, IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, CD274 ANTIGEN))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-69*01 (94%) (IGHD)-IGHJ1